Thursday, October 1, 2026
← Back to archivePolicy
Policy•STAT News•Oct 1, 2026
Opinion: Claude analyzed my genome in 30 minutes. Now we need standards for the results
background ▾
- •AI can now perform clinically meaningful genome analysis at a fraction of historical cost and time, but without established standards for medical reliability or accuracy validation
- •The absence of consensus standards for AI-assisted genomic interpretation poses regulatory and clinical safety risks as these tools proliferate beyond expert settings
- •Different sequencing technologies and reference genomes create variable outputs that could mislead patients or clinicians without clear quality benchmarks and standardization protocols
Policy•Endpoints News•Sep 30, 2026
CMS finalizes GLOBE Medicare demo but savings trail projections
background ▾
- •CMS has finalized the GLOBE Medicare demo program aimed at drug price reduction, but achieved savings substantially lag initial projections
- •The shortfall between expected and realized savings suggests structural challenges in implementing pharmaceutical cost controls within the existing Medicare framework
- •Future viability and expansion of the GLOBE program will depend on CMS's ability to identify root causes of underperformance and strengthen program mechanisms
Centers for Medicare and Medicaid Services
→ Read original articlePolicy•KFF•Sep 30, 2026
The Legal and Policy Landscape of Crisis Pregnancy Centers
background ▾
- •The Trump administration's explicit endorsement of CPCs through moms.gov represents a significant policy shift toward government-supported expansion of these unregulated pregnancy centers.
- •CPCs employ deliberate strategies including co-location near abortion clinics, deceptive marketing, and delay tactics that medical organizations argue undermine informed consent.
- •Monitor federal and state funding mechanisms for CPCs and potential regulatory attempts to standardize or restrict their practices, particularly as CPCs attempt to fill maternity care gaps in abortion-restrictive states.
Heartbeat InternationalNational Institute for Family and Life Advocates (NIFLA)Care Net
→ Read original articlePolicy•Fierce Biotech•Sep 30, 2026
Beam Therapeutics sues base editing rival, claims former scientist stole secrets
background ▾
- •Beam alleges former employee Wang founded a competitor company while employed, accessed restricted files, and used proprietary delivery system information to create a direct AATD competitor—representing a potential trade secret theft in a high-value gene-editing program
- •Serapha Bio, which licensed YOLT-202 rights outside China for $230M and is merging with Boundless Bio, now faces litigation that could cloud its ability to develop SERP-01 or force costly licensing negotiations/settlements
- •Gene-editing IP disputes are intensifying (Beam recently lost to Prime Medicine on an AATD collaboration claim); outcomes will shape competitive positioning in base editing and may influence investor confidence in early-stage gene therapy startups
Beam TherapeuticsYolTech TherapeuticsSerapha BioBEAM-302YOLT-202SERP-01
→ Read original articlePolicy•Endpoints News•Sep 30, 2026
New biotech alliance tells Congress to fight for US dominance
background ▾
- •Industry advocacy group mobilizing congressional engagement around US biotech competitiveness concerns
Market Access
Market Access•Fierce Biotech•Sep 30, 2026
GSK continues to stock up on Wave's RNA drugs with liver-focused program
background ▾
- •GSK is systematically exercising options under its original $170M 2022 Wave collaboration, now having selected 5 of 8 available programs, signaling sustained confidence in Wave's SpiNA siRNA design and PRISM platform
- •This hepatology program complements GSK's existing clinical-stage siRNA candidate gatuzosiran, positioning GSK with multiple RNA-based approaches in liver disease
- •Watch for the status of Wave's three remaining programs approaching candidate selection and GSK's clinical progress with both gatuzosiran and this new hepatic candidate
GSKWave Life Sciencesgatuzosiran
→ Read original articleMarket Access•Fierce Biotech•Oct 1, 2026
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
background ▾
- •Sanofi is committing $8 billion total ($1B upfront + $7B milestones) to four Regeneron early-stage immunology assets as a direct strategy to replace revenue from Dupixent's 2031 patent cliff.
- •The deal resolves 2024 litigation and settles trust issues between partners, signaling CEO Garijo's priority to stabilize and strengthen the Sanofi-Regeneron relationship despite recent tensions over commercialization transparency.
- •Watch for: REGN20423 (IL-13 mAb) clinical trial progression, initiation of the three preclinical programs in 2025, lunsekimig COPD phase 3 readout (potential collaboration expansion), and Regeneron's muscle preservation data for trevogrumab in weight management.
SanofiRegeneron PharmaceuticalsNovo NordiskDupixentREGN20423lunsekimig
→ Read original articleMarket Access•Endpoints News•Sep 30, 2026
Varda gets $251M to make medicines in space, a long-sought area for drugs
background ▾
- •Varda raised $251M Series D, signaling significant investor backing for space-based pharmaceutical manufacturing despite unproven commercial model
- •Space manufacturing remains conceptually attractive to pharma but faces major hurdles: FDA regulatory precedent is limited, cost-benefit versus Earth-based production is unclear, and no marketed drugs have been manufactured in space at scale
Varda Space Industries
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Sep 30, 2026
Merck’s anti-TL1A antibody secures a win in ph. 2 hidradenitis suppurativa trial
background ▾
- •Tulisokibart achieved strong dose-dependent efficacy in HS phase 2b (72% HiSCR50 at high dose), supporting phase 3 advancement and broadening the asset's commercial potential beyond IBD.
- •Mixed clinical track record for tulisokibart in 2024 (phase 3 win in UC offset by phase 2 failure in systemic sclerosis) raises questions about mechanistic applicability across immune-mediated diseases.
- •Densely competitive HS landscape with approved TNF inhibitors, oral JAK1 inhibitors (povorcitinib phase 3 wins in March 2025), and emerging IL-1β biologics may constrain tulisokibart's market positioning and reimbursement negotiating power.
Merck & Co.Prometheus BiosciencesAvalo Therapeuticstulisokibartabdakibartpovorcitinib
→ Read original articleClinical Trials•Fierce Biotech•Sep 30, 2026
Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancer
background ▾
- •BO-112 met primary endpoint in Phase 2b with 61% visual and pathological response in localized BCC; 56-62% response in high-risk head and neck lesions demonstrates clinically meaningful efficacy in the target population
- •Excellent safety profile with no serious adverse events and no Grade 3+ treatment-related AEs; 91% experienced Grade 1 AEs that resolved within 3 days in 88% of patients, supporting tolerability advantage
- •Phase 3 initiation timing and competitive positioning against approved alternatives (Libtayo, Odomzo, Erivedge) will be critical to market success; parallel development in melanoma, sarcoma, and HCC may provide additional value
Highlight TherapeuticsMerck/MSDSanofiBO-112KeytrudaLibtayo
→ Read original articleClinical Trials•STAT News•Oct 1, 2026
Opinion: I studied GLP-1 use in children. The results are reassuring
background ▾
- •GLP-1 prescriptions in children 8-11 increased 310-fold since 2019, but only 0.6% of the 3.5 million obese children in this age group received them, concentrated in severe cases with complications
- •94% of prescribed children had severe obesity with documented adult-onset complications (sleep apnea, prediabetes, hypertension, fatty liver disease), suggesting clinician restraint and appropriate patient selection
- •FDA approval for children under 12 could expand coverage and reduce disparities, but risks liberal use in milder cases—long-term safety data on growth, puberty, and development remain critical unknowns
GLP-1 receptor agonist
→ Read original articleClinical Trials•Fierce Biotech•Sep 30, 2026
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
background ▾
- •EloraTZP demonstrated superior weight loss (23.3% average, 54.1 lbs at highest dose) in the challenging diabetes-comorbid obesity population, outperforming retatrutide data and matching tirzepatide efficacy in non-diabetic patients
- •High discontinuation rate (27%) due primarily to gastrointestinal adverse events in combination arm raises serious tolerability and commercial viability questions; phase 3 titration strategy will be critical
- •Watch for phase 3 results starting Q4 2026 and Lilly's ability to optimize dosing/titration to preserve efficacy while reducing GI tolerability burden in competitive obesity market
Eli LillyEndeavor HealtheloraTZPeloralintideZepbound
→ Read original articleClinical Trials•Fierce Biotech•Sep 30, 2026
Connect’s Dupixent rival reduces COPD attacks by 85%, but misses a secondary goal
background ▾
- •Rademikibart achieved 81% reduction in COPD treatment failure and completely eliminated hospitalizations/ED visits in the 28-day window, a commercially significant finding given the $6B annual ED-related costs in acute COPD exacerbations
- •The missed FEV1 secondary endpoint raises questions about the drug's mechanism in COPD and complicates the regulatory strategy, particularly as Connect still intends to propose FEV1 as an endpoint for asthma phase 3 despite the mechanism challenges acknowledged by management
- •Phase 3 FDA engagement imminent; success here is critical given the prior asthma study failure to reach statistical significance and the need to establish a differentiated position against Dupixent in an increasingly competitive IL-4Rα space
Connect BiopharmaSimcere PharmaceuticalSanofirademikibartDupixent
→ Read original article